⚠️ Small Study / Early Comparative Evidence
A randomized, double-blind trial at 38 sites evaluated intranasal mebufotenin benzoate in 193 adults with treatment-resistant depression. Participants had not responded to two to five antidepressant trials during the current episode. They received 8 mg, 12 mg, or a 0.3-mg comparator alongside psychological support. Both active doses produced greater symptom reductions from day 2 through day 57. The study also examined tolerability and recovery after dosing, with further evaluation planned in phase 3.
Clinical Considerations
- At day 29, MADRS improvement exceeded the comparator by 5.3 points with 12 mg and 6.2 points with 8 mg; both P=.003.
- Day-29 response rates were 34.8% with 8 mg, 34.2% with 12 mg, and 12.2% with the comparator.
- Treatment-emergent adverse events affected 76.1%, 84.9%, and 73.0% of participants in the 8-mg, 12-mg, and comparator groups, respectively.
- Nearly all adverse events were mild or moderate. One 12-mg participant experienced two severe panic attacks considered treatment related.
- Within two hours, 85% of the 8-mg group and 78% of the 12-mg group met discharge-readiness criteria.
- Actual discharge was prohibited before four hours. Planned phase 3 studies will assess longer-term durability and include an intermediate dose.
Practice Applications
- The article presents symptom improvement and postdose recovery as separate findings, addressing both antidepressant effects and treatment-session logistics.
- Authors describe potential access and convenience benefits from shorter monitoring and fewer visits compared with other treatments discussed in the article.
- Functional unblinding and dose response remain explicit areas for further investigation in the planned phase 3 program.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS